Canaccord Genuity Lowers AngioDynamics Stock Price Target

Analysts cite concerns about the medical device company's performance and outlook.

Apr. 6, 2026 at 3:26pm

Got story updates? Submit your updates here. ›

An extreme close-up of highly detailed, industrial medical device components and machinery, conveying a sense of the complex financial and technological forces shaping the healthcare industry.The intricate inner workings of the medical device industry reflect the complex financial and technological forces shaping the future of healthcare innovation.Latham Today

Canaccord Genuity Group, an investment bank, has lowered its target price for shares of AngioDynamics (NASDAQ:ANGO) from $18.00 to $16.00 and maintained a 'buy' rating on the stock. The analysts cited concerns about the medical instruments supplier's recent performance and future outlook.

Why it matters

This downgrade from a prominent investment firm could signal broader challenges facing AngioDynamics as it competes in the highly competitive medical device market. Investors will be closely watching the company's next earnings report and guidance for signs of improvement or further struggles.

The details

In a note to investors, Canaccord Genuity analysts lowered their price target on AngioDynamics shares, citing the company's recent financial performance. The analysts maintained a 'buy' rating on the stock, but the reduced target price suggests they see limited upside potential in the near term.

  • Canaccord Genuity issued the updated price target and rating on Monday, April 6, 2026.

The players

Canaccord Genuity Group

A global investment bank and financial services firm that provides research, advisory, and trading services to institutional and corporate clients.

AngioDynamics

A medical technology company that develops, manufactures, and markets minimally invasive medical devices for vascular access, peripheral vascular intervention, and interventional oncology.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely watching AngioDynamics' upcoming earnings report and guidance to see if the company can address the concerns raised by Canaccord Genuity analysts.

The takeaway

This downgrade from a prominent investment firm highlights the challenges facing AngioDynamics as it navigates the competitive medical device market. The company's ability to improve its financial performance and outlook will be crucial in determining the future direction of its stock price.